Redefining fatty liver disease: an international patient perspective.

Autor:	Shiha G; European Liver Patients' Association (ELPA), Brussels, Belgium; World Hepatitis Alliance, London, UK; African Liver Patient Association (ALPA), Cairo, Egypt; Association of Liver Patients Care (ALPC), Mansoura, Egypt; Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. Electronic address: g_shiha@hotmail.com., Korenjak M; European Liver Patients' Association (ELPA), Brussels, Belgium; Association SLOVENIA HEP, Maribor, Slovenia., Eskridge W; Fatty Liver Foundation, Boise, ID, USA., Casanovas T; European Liver Patients' Association (ELPA), Brussels, Belgium; Asociación Catalana de Pacientes Hepáticos (ASSCAT), Barcelona, Spain., Velez-Moller P; World Hepatitis Alliance, London, UK; Guatemala Liver Patients Association, Guatemala City, Guatemala., Högström S; European Liver Patients' Association (ELPA), Brussels, Belgium; Finnish Kidney and Liver Association, Helsinki, Finland., Richardson B; The Liver Foundation, Woolloongabba, QLD, Australia., Munoz C; Yellow Warriors Society Philippines (YWSP), Manila, Philippines., Sigurðardóttir S; The European Coalition for People Living with Obesity (EASO ECPO), Dublin, Ireland., Coulibaly A; World Hepatitis Alliance, London, UK; African Liver Patient Association (ALPA), Cairo, Egypt; Association for the Promotion of Health and Development in Mali (APSAD/MALI), Bamako, Mali; Association of the Malians of Washington DC (AMAW), Washington DC, USA., Milan M; European Liver Patients' Association (ELPA), Brussels, Belgium; Hepar Centar, Bitola, North Macedonia., Bautista F; Fundación Sayani, Jujuy, Argentina., Leung NWY; ASIAHEP Hong Kong, Hong Kong Special Administrative Region, China., Mooney V; The European Coalition for People Living with Obesity (EASO ECPO), Dublin, Ireland., Obekpa S; African Liver Patient Association (ALPA), Cairo, Egypt; Advocacy for the Prevention of Hepatitis in Nigeria (APHIN), Benue State, Nigeria., Bech E; La Federación Nacional de Enfermos y Trasplantados Hepáticos (FNETH), Madrid, Spain., Polavarapu N; Save the Liver Foundation, Hyderabad, India., Hamed AE; Arabic Association for the Study of Diabetes and Metabolism, Cairo, Egypt; Department of Internal Medicine, Hepatology, and Diabetes, Egyptian Military Medical Academy, Cairo, Egypt., Radiani T; European Liver Patients' Association (ELPA), Brussels, Belgium; Hepatitis C Cured Patient Association, Tbilisi, Georgia., Purwanto E; Budi Lukmanto Foundation, North Jakarta, Indonesia., Bright B; Live Well Initiative (LWI), Lagos, Nigeria., Ali M; National Liver Foundation of Bangladesh, Dhaka, Bangladesh., Dovia CK; World Hepatitis Alliance, London, UK; African Liver Patient Association (ALPA), Cairo, Egypt; Cedaku Foundation of Ghana, Ho, Ghana., McColaugh L; Leverforeningen, Odense C, Denmark., Koulla Y; Cyprus Liver Patients Association, Nicosia, Cyprus., Dufour JF; Swiss NASH Foundation, Bern, Switzerland; University Clinic for Visceral Surgery and Medicine, Inselspital, Bern, Switzerland; Department of Biomedical Research, University of Bern, Bern, Switzerland., Soliman R; European Liver Patients' Association (ELPA), Brussels, Belgium; Association of Liver Patients Care (ALPC), Mansoura, Egypt; Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt; Department of Tropical Medicine, Faculty of Medicine, Port Said University, Port Said, Egypt., Eslam M; Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, Australia. Electronic address: mohammed.eslam@sydney.edu.au.
Jazyk:	angličtina
Zdroj:	The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Jan; Vol. 6 (1), pp. 73-79. Date of Electronic Publication: 2020 Oct 05.
DOI:	10.1016/S2468-1253(20)30294-6
Abstrakt:	Despite its increased recognition as a major health threat, fatty liver disease associated with metabolic dysfunction remains largely underdiagnosed and undertreated. An international consensus panel has called for the disease to be renamed from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD) and has suggested how the disease should be diagnosed. This Viewpoint explores the call from the perspective of patient advocacy groups. Patients are well aware of the negative consequences of the NAFLD acronym. This advocacy group enthusiastically endorses the call to reframe the disease, which we believe will ultimately have a positive effect on patient care and quality of life and, through this effect, will reduce the burden on health-care systems. For patients, policy makers, health planners, donors, and non-hepatologists, the new acronym MAFLD is clear, squarely placing the disease as a manifestation of metabolic dysfunction and improving understanding at a public health and patient level. The authors from representative patient groups are supportive of this change, particularly as the new acronym is meaningful to all citizens as well as governments and policy makers, and, above all, is devoid of any stigma. (Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu